ReviewNaunyn-Schmiedeberg's archives of pharmacology2025
Cells, tissues, and vigilance: navigating the complex landscape of biovigilance in India.
Review in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biovigilance plays a crucial role in healthcare safety by monitoring and managing medical products of human origin (MPHO) to protect patient health. Initially centred on blood safety, known as haemovigilance, biovigilance has grown to cover a wide range of biological products, including tissues, organs, and cell-based therapies. The World Health Organization (WHO) has been a key in developing international standards and advocating for best practices in biovigilance. At a national level, programs such as India's Haemovigilance Programme (HvPI) work to increase transparency and improve reporting of adverse reactions. Today, biovigilance functions as an integrated safety system addressing ethical, regulatory, and clinical challenges linked to human-derived medical products, thus promoting safer global healthcare practices. This review presents a comprehensive overview of biovigilance, detailing its historical development, core areas, and current practices. Key initiatives, like the HvPI and Project Notify, exemplify effective approaches to adverse reaction monitoring and foster transparency in healthcare. Through these frameworks, biovigilance enhances patient safety, ensuring a more secure and trustworthy healthcare delivery worldwide.
Indexed as
Identifiers
40663157What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.